The next step should be the evaluation of the significance of TXR1/TSP1 expression in taxanes' chemosensitivity in other tumour types such as breast and ovarian cancer, where taxanes are commonly used in the daily clinical practice. This evidence concerns the gene PRR13 and ovarian carcinoma.